Clozapine (Clozaril)
Second generation antipsychotic (dopamine, serotonin, norepinephrine receptor antagonist (dopamine D2, serotonin 5-HT2, norepinephrine alpha-2))
- Schizophrenia3
- Use after 2 failed trials in schizophrenia1
- Mania/mixed (treatment resistant)4
- Prevents aggression/suicide in schizophrenia1
Features
Dosing
Titrate slowly to prevent orthostatic hypotension, seizures, and myocarditis.
Start 12.5 mg once or twice daily. If tolerated, increase by 25–50 mg/day to reach a target of 150–225 mg twice daily (300–450 mg/day) by the end of 2 weeks. Use the lower and slower ranges for sensitive patients and older adults.
After reaching 300-450 mg/day, adjust based on response and serum level.
Lower target doses often used in bipolar (50-150 mg).
INTERACTIONS: Raise by 2x if using with carbamazepine. Lower 2-3x if using strong 1A2 inhibitor like fluvoxamine.
Fluvoxamine Strategy for Tolerability
By pairing clozapine with low dose fluvoxamine, you can reduce side effects and increase efficacy (it blocks the metabolite (norclozapine). Use this strategy carefully only after stabilizing them on clozapine.
Clozapine is metabolized by 1A2, and fluvoxamine blocks this enzyme, raising clozapine approximately 3x. After stabilizing the clozapine dose, check level. Then lower clozapine (divide dose by 3) and add fluvoxamine 50 mg/d. Recheck clozapine serum levels 2 weeks later.
Do not use this strategy if manic risk (fluvoxamine may trigger that).
Management
Use after 2 failed antipsychotic trials. Chance of responding is 80% if started in first 3 years of illness, but 30% if started later. Useful for problematic aggression, suicidality, and tardive dyskinesia. Can use in treatment resistant bipolar if patient has frequent manic/psychosis. Clozapine leads to fuller recoveries and longer lives (by 10 years) compared to other antipsychotics.
Monitor CBC according to post-REMS guide.
TOLERABILITY: Weight gain, sedation, anticholinergic, drooling (use rubber pillow). Monitor and treat constipation on it aggressively, starting with peri-colace. Monitor side effects with a self-rated scale at each visit.
RISKS: Neutropenia (1:100 risk if not monitored), metabolic, orthostasis (falls), cardiotoxicity, QTc prolongation, seizures, severe constipation (potentially fatal), pneumonia.
No risk of TD. Little-to-no risk of prolactinemia, akathisia, EPS.
EMR Text
Schizophrenia (treatment resistant)
Clozapine use based on FDA approval in treatment-resistant schizophrenia.
Clozapine risks, including neutropenia, cardiac, metabolic, constipation, and seizures, reviewed with patient.
Bipolar Mania/Schizoaffective (treatment resistant)
Clozapine use based on trials in treatment-resistant manic/psychotic disorders, including Bipolar I and Schizoaffective Disorder.
Clozapine risks, including neutropenia, cardiac, metabolic, constipation, and seizures, reviewed with patient.